Mary Haak-Frendscho, Ph.D., joined Versant in 2016 as CEO of the Blueline Bioscience discovery engine based at the MaRs center in Toronto’s Discovery District. She also is a Venture Partner for the firm and is based in Toronto.
Mary brings more than 25 years of proven industry and entrepreneurial experience to support Versant’s goal of building a world-class Canadian biotech portfolio in partnership with academics and entrepreneurs throughout the country. She currently serves on the board of directors of Versant-backed Northern Biologics based in Toronto.
Mary previously served as CEO at Igenica, chairman of Compugen, president and CSO of Takeda SF USA, and held R&D leadership roles at Genentech, Abgenix and XOMA. She holds degrees from the University of Michigan, Washington University, Stony Brook University and the University of Wisconsin.